Skip to main content

Table 2 Treatment characteristics- Patients receiving SCT

From: Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001–2010: a retrospective, population based analysis

  Patients ≥ 60 years of age Patients 61–65 years of age
N (%) N (%)
Induction treatment
 VAD 90 (42,6) 32 (39,5)
 Cy/Dex 120 (56,5) 49 (60,5)
 Vel/Dex 2 (0,9) 0
Consolidation
 IFN 38 (17,9) 10 (12,3)
 Bortezomib 25 (11,9) 7 (8,6)
 No consolidation 149 (70,2) 64 (79,1)
Treatment response
 Progressive disease 1 (0,6) 3 (3,6)
 Stable disease 7 (3,2) 1 (1,2)
 Minimal response 9 (4,2) 2 (2,4)
 Partial response 102 (48,1) 49 (59.0)
 Complete response 57 (27,2) 19 (22,9)
 Not evaluable 36 (16,7) 9 (10,9)
  1. VAD vincristin- adriamycin-dexamethasone, Cy/Dex cyclophosphamide-dexamethasone, Vel /Dex Bortezomib-dexamethasone, IFN α- Interferon